CRIS · Curis Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $3.18M | $2.75M | $2.38M | - | $2.93M | $2.55M | $2.09M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.45M | - | $6.43M | $7.46M | $8.54M | - | $9.72M | $10.25M | $9.62M | - |
| SG&A | $5.07M | - | $3.65M | $3.53M | $3.98M | - | $3.75M | $4.79M | $4.89M | - |
| Total Operating Expenses | $11.52M | - | $10.10M | $11.00M | $12.54M | - | $13.50M | $15.06M | $14.55M | - |
| D&A | $8.0K | - | - | - | $59.0K | - | - | - | $64.0K | - |
| Operating Income | ($11.52M) | - | ($6.92M) | ($8.25M) | ($10.16M) | - | ($10.57M) | ($12.51M) | ($12.47M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($24.20M) | - | ($7.73M) | ($8.59M) | ($10.62M) | - | ($10.09M) | ($11.80M) | ($11.88M) | - |
| EPS - Basic | ($1.25) | - | ($0.49) | ($0.68) | ($1.25) | - | ($1.70) | ($2.03) | ($2.05) | - |
| EPS - Diluted | ($1.25) | - | ($0.49) | ($0.68) | ($1.25) | - | ($1.70) | ($2.03) | ($2.05) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.00M | $5.06M | $9.05M | $10.14M | $20.28M | $20.00M | $20.85M | $10.00M | $29.96M | $26.68M |
| Accounts Receivable | - | $0 | $3.24M | $2.75M | $2.31M | $3.35M | $2.98M | $2.55M | $2.15M | $2.79M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.74M | $5.61M | $4.45M | $4.10M | $5.10M | $3.02M | $3.82M | $2.45M | $3.63M | $3.17M |
| Current Assets | $16.61M | $6.92M | $13.91M | $14.42M | $24.81M | $26.39M | $26.94M | $34.52M | $46.07M | $60.91M |
| Total Assets | $29.69M | $19.97M | $27.64M | $29.23M | $39.33M | $41.27M | $42.47M | $50.41M | $62.02M | $77.28M |
| Current Liabilities | $14.97M | $14.08M | $19.91M | $19.37M | $20.12M | $19.03M | $22.03M | $19.37M | $11.30M | $13.52M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.98M | $14.50M | $42.33M | $43.22M | $45.93M | $47.26M | $51.21M | $51.11M | $52.56M | $57.61M |
| Stockholders' Equity | $12.71M | $5.46M | ($14.69M) | ($13.99M) | ($6.61M) | ($6.00M) | ($8.73M) | ($694.0K) | $9.46M | $19.67M |
| Retained Earnings | ($1.27B) | ($1.25B) | ($1.27B) | ($1.26B) | ($1.25B) | ($1.24B) | ($1.23B) | ($1.22B) | ($1.21B) | ($1.20B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.00M) | - | - | - | ($7.25M) | - | - | - | ($13.23M) | - |
| Investing Cash Flow | $0 | - | - | - | $0 | - | - | - | $18.91M | - |
| Financing Cash Flow | $18.94M | - | - | - | $7.54M | - | - | - | ($2.41M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -218.0% | -300.1% | -426.8% | - | -360.5% | -491.4% | -597.7% | - |
| EBITDA margin | - | - | - | - | -424.3% | - | - | - | -594.7% | - |
| Net margin | - | - | -243.4% | -312.6% | -446.1% | - | -344.3% | -463.6% | -569.3% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 202.5% | 271.3% | 358.8% | - | 331.7% | 402.7% | 461.0% | - |
| SG&A / Revenue | - | - | 115.0% | 128.3% | 167.4% | - | 128.0% | 188.2% | 234.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -81.5% | - | -28.0% | -29.4% | -27.0% | - | -23.8% | -23.4% | -19.1% | - |
| Return on equity | -190.4% | - | 52.6% | 61.4% | 160.7% | - | 115.5% | 1700.7% | -125.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.11 | 0.49 | 0.70 | 0.74 | 1.23 | 1.39 | 1.22 | 1.78 | 4.08 | 4.51 |
| Quick ratio | 1.11 | 0.49 | 0.70 | 0.74 | 1.23 | 1.39 | 1.22 | 1.78 | 4.08 | 4.51 |
| Cash ratio | 1.00 | 0.36 | 0.45 | 0.52 | 1.01 | 1.05 | 0.95 | 0.52 | 2.65 | 1.97 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.34 | 3.66 | -1.88 | -2.09 | -5.95 | -6.88 | -4.86 | -72.64 | 6.56 | 3.93 |
| Liabilities / Assets | 0.57 | 0.73 | 1.53 | 1.48 | 1.17 | 1.15 | 1.21 | 1.01 | 0.85 | 0.75 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.11 | 0.09 | 0.06 | - | 0.07 | 0.05 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 373d | 365d | 355d | - | 371d | 365d | 377d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.8x | - | - | - | - | - | - | - | 6.6x | - |
| P / S | - | - | 8.2x | 10.7x | 7.5x | - | 10.9x | 15.8x | 30.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | 8.4% | 8.0% | 14.1% | - | 3.5% | 15.9% | -9.2% | - |
| Revenue CAGR (3y) | - | - | 4.0% | 4.7% | 5.0% | - | -1.2% | 3.7% | -1.6% | - |
| Revenue CAGR (5y) | - | - | 3.0% | 3.1% | -2.6% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -13.4% | - | 34.5% | 34.1% | 18.5% | - | 14.6% | -3.1% | -7.2% | - |
| Net income growth (YoY) | -127.9% | - | 23.4% | 27.2% | 10.6% | - | 17.1% | 1.3% | -2.7% | - |
| EPS growth (YoY) | 0.0% | - | 71.2% | 66.5% | 39.0% | - | 20.2% | -1591.7% | -1608.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -68.2% | -1915.3% | - | - | - | - | -74.1% | -57.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$9.44M totalReportable Segment$9.44M · 100.0%
Product / service
$9.40M totalGross Royalty Revenue$9.40M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CURIS INC against the 5 most active filers in the same SIC group.